Metsera said it has struck a revised merger agreement with Pfizer that values the company at up to $86.25 per share in cash.

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...

Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.

Metsera, the US biotech with a pipeline of next-generation metabolic hormone weight loss drugs, has agreed a sale to Pfizer ...

Metsera stock was tumbling on Monday after Pfizer agreed to buy the weight-loss drug start-up in a deal that could end up ...

Metsera said that Pfizer will pay up to US$86.25 a share, including US$65.60 a share in cash initially, plus potential additional payments of up to US$20.65 a share for hitting certain milestones.

Metsera stock toppled Monday after the buyout battle with Pfizer and Novo Nordisk ended. Pfizer will acquire Metsera for up ...

The Genesis Prize Foundation (GPF) led by its Co-Founder and Chairman Stan Polovets today announced Israeli actor and ...

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

Israeli actor Gal Gadot has been awarded Israel’s Genesis Prize in recognition of her strong support for the country at a ...